Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06442475
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-05-29
Brief Title:
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Sponsor:
University of Washington
Organization:
University of Washington
Study Overview
Official Title:
Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial tests the safety side effects and effectiveness of mosunetuzumab in treating patients with slow growing indolent B-cell lymphoma Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread
Detailed Description:
OUTLINE
Patients receive mosunetuzumab intravenously IV over 2-4 hours on days 1 8 15 and 22 Patients also undergo blood sample collection and positron emission tomography PETcomputed tomography CT on study Patients may undergo CT andor magnetic resonance imaging MRI as clinically indicated and may undergo collection of oral andor rectal swabs on study
After completion of study treatment patients are followed up at week 13 at 6 months and then for up to 5 years per institutional standards
Patients receive mosunetuzumab intravenously IV over 2-4 hours on days 1 8 15 and 22 Patients also undergo blood sample collection and positron emission tomography PETcomputed tomography CT on study Patients may undergo CT andor magnetic resonance imaging MRI as clinically indicated and may undergo collection of oral andor rectal swabs on study
After completion of study treatment patients are followed up at week 13 at 6 months and then for up to 5 years per institutional standards
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 20417 | OTHER | Fred HutchUniversity of Washington Cancer Consortium | None |
| NCI-2024-02289 | REGISTRY | None | None |